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Abstract: Statistical studies have demonstrated that various agents may reduce the risk of cancer’s 
development. One of them is activity of flavin-dependent enzymes such as flavin-containing 
monooxygenase (FMO)GS-OX1, FAD-dependent 5,10-methylenetetrahydrofolate reductase 
and flavin-dependent monoamine oxidase. In the last decade, many papers concerning their 
structure, reaction mechanism and role in the cancer prevention were published. In our work, we 
provide a more in-depth analysis of flavin-dependent enzymes and their contribution to the 
cancer prevention. We present the actual knowledge about the glucosinolate synthesized by 
flavin-containing monooxygenase (FMO)GS-OX1 and its role in cancer prevention, discuss the 
influence of mutations in FAD-dependent 5,10-methylenetetrahydrofolate reductase on  
the cancer risk, and describe FAD as an important cofactor for the demethylation of 
histons. We also present our views on the role of riboflavin supplements in the prevention  
against cancer. 
Keywords: flavin-containing monooxygenase; methylenetetrahydrofolate reductase; 
monoamine oxidase 
 
1. Introduction 
Riboflavin, 7,8-dimethyl-10-ribityl-isoalloxazine, is a water-soluble vitamin present in a wide 
variety of foods, such as milk, offal, cereals or dark-green leafy vegetables [1,2]. It is well established 
that riboflavin participates in a diversity of redox reactions which absolutely play a key role in the 
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function of human cells, through the cofactors FMN and FAD, which act as electron carriers. 
Insufficient intake of riboflavin can lead to disturbances in reactions of intermediary metabolism, 
together with the functional implications [1]. It was also demonstrated that riboflavin can play an 
important role in the development and progression of cancer [3]. On the other hand, it can protect 
against cancer or support chemotherapy [4–6]. 
In connection with an increasing interest in the role of riboflavin in protecting against cancer it was 
important and necessary to present the actual knowledge about the relationship between riboflavin 
intake, flavin-dependent enzyme, and the risk of cancer.  
2. Role of Flavin-Containing Monooxygenase in Glucosinolate Synthesis 
Glucosinolates (GSLs) are sulfur-rich secondary plant metabolites containing β-thioglucopyranose 
residue and N-hydroxyiminosulfate ester which form the core linked to a structurally diverse amino 
acid-derived side chain [7]. Based on their amino acid precursors GSLs are classified into three major 
groups: aliphatic glucosinolates, derived from Ala, Leu, Ile, Val, and Met; benzenic glucosinolates, 
derived from Phe or Tyr, and indolic glucosinolates, derived from Trp [8,9]. The most abundant of all 
GSLs is indole glucosinolate which is found in high concentration in cruciferous vegetables such as 
broccoli, cabbage, cauliflower or Brussels sprouts [7,10–12]. Epidemiological studies have shown that 
a diet rich in glucosinolates correlates with a decreased risk of developing many common cancers [10–14]. 
The anticarcinogenic effect of GSLs is probably associated with the properties of indoles and 
isothiocyanates, the certain products of glucosinolates hydrolysis. These compounds are known to 
influence the activity of phase I and II biotransformation enzymes involved in the modulation of 
metabolism of carcinogenic and/or mutagenic compounds, thereby preventing the formation of 
electrophilic intermediates which can bind to DNA [15–17]. The key enzyme in glucosinolate 
biosynthesis is flavin-dependent monooxygenase and activity of this enzyme as well as flavin levels in 
plant indirectly influences the risk of cancer in humans. 
Biosynthesis of glucosinolate generally occurs through three independent stages: chain elongation 
of selected precursor amino acid; formation of the core structure and secondary modification of the 
aliphatic chain [7–9]. Initial reaction in GSLs formation, transamination takes place in the cytosol. 
Side chain elongation occurs in the chloroplast and the core structure formation is catalyzed by 
enzymes associated with the endoplasmatic reticulum membranes as well as those sited in the  
cytosol [8]. However not much information is known about the localization of the final step in GSL 
biosynthesis, and the side chain modifications of the glucosinolate are of particular importance because 
the biological activity of the glucosinolate hydrolysis products is determined to a large extent by the 
structure of the side chain [14]. Additionally, secondary modifications together with the side-chain 
elongation are responsible for more than 120 known glucosinolate structures [8].  
Plant flavin-containing monooxygenases (FMOs) are proteins of about 50 kDa with the  
FMO-identifying motif (“FxGxxxHxxxY/F”) and the conserved “GxGxxG” motif for binding FAD 
and NADPH. FMOs catalyze the transfer of one atom of molecular O2 to a large variety of small, 
nucleophilic compounds, among them sulfur-containing substrates, thus rendering them more  
polar [18–20]. The catalytic activity of these enzymes is carried out mainly through the prosthetic 
group FAD and cofactor NADPH. FAD is the major electron carrier in the oxidation-reduction 
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processes catalyzed by various enzymes. The electron donor in the S-oxygenation of methylthioalkyl is 
NADPH [19]. In the catalytic cycle, FAD is first reduced to FADH2 through a hydride ion transfer 
from NADPH. In the second step FADH2 binds molecular oxygen at the 4α position of the 
isoalloxazine ring, resulting in a 4α-hydroperoxyflavin adenine dinucleotide (FAD-OOH)  
formation [19,20]. The hydride ion transfer from NADPH to isoalloxazine ring was proposed by 
Eswaramoorthy et al. [19]. According to their assumptions the nicotinamide portion of NADPH  
stacks with the flavin of FAD in a novel fashion. Atom C2 of the nicotinamide base is 3.35 Å from N5 
of the flavin ring and the hydride ion transfer takes place through these two atoms. The N5 atom of  
the reduced flavin moiety makes a hydrogen bond with O7 of the nicotinamide. In the  
enzyme-FAD-NADPH complex the prostetic group exists as a FADH2 and the cofactor is in the 
protonated form as a NADP+. In this state, the FADH2 is ready to bind molecular oxygen. This 
molecular oxygen is located near the flavin ring and is readily available for 4α-hydroperoxyflavin 
formation [19]. The isoalloxazine moiety attached to the proximal peroxy-oxygen is  
electron-withdrawing, polarizing the O–O bond and activating it for heterolytic cleavage [20]. In this 
conformation, the enzyme awaits the S-containing substrate, which needs a free electron pair which 
can enter into the active site. When a suitable substrate with a nucleophilic atom, such as the S in 
methylthioalkyl, binds productively to the protein/FAD-OOH complex, it is oxygenated to SO through 
the OOH moiety. The other oxygen atom reacts to form water. NADP is released and the binding of 
NADPH starts a new cycle (Figure 1) [18,19].  
Flavin-containing monooxygenases (FMO)GS-OX, have been identified in Arabidopsis as enzymes 
catalyzing the first step in side chain modification of aliphatic glucosinolates, the S-oxygenation from 
methylthioalkyl to methylsulphinylalkyl GSLs. According to phylogenetic analysis, FMOGS-OX are 
assigned to Clade III of plant FMOs phylogenetic tree [11,12,14]. Within enzymes of Clade III the 
characteristic amino acid motif “HCTGYK” was also found [18]. Li et al. [14] analyzed subcellular 
localization of these enzymes by fusing the FMOGS-OX with the yellow fluorescent protein (YFP). 
However the catalytic function of this enzyme was observed in cytosol, YFP signals were also detected 
in the ER. Authors suggested that the ER-located fluorescence signal was connected with the early 
phase of biosynthesis or transportation of FMOGS-OX [14]. 
Plant FMOs do not transform physiological nucleophiles, i.e., methionine, cysteine and glutathione 
and do not show such a broad substrate specificity as the animal FMOs [11,18]. Hansen et al. [11] 
have shown that the S-oxygenating activity of FMOGS-OX from Arabidopsis is selective for potential 
substrates containing a methylthiol moiety. Moreover, the enzyme product is a pure epimer and its 
sulfoxide group has the RS configuration which indicates that the enzyme is stereospecific [7].  
3. Relationship between FAD-Dependent 5,10-Methylenetetrahydrofolate Reductase and  
Cancer Risk  
5,10-Methylenetetrahydrofolate reductase (MTHFR ) is present in both prokaryotic and eukaryotic 
organisms [21–27] and the sequences of human methylenetetrahydrofolate reductase show clear 
homology with their bacterial analogs [28]. MTHFR catalyze the NAD(P)H-dependent reduction of 
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate.  
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Figure 1. Role of FAD in S-oxygenation of glucosinolate. FAD is reduced to FADH2 
through a hydride ion transfer from NADPH (1, 2); FADH2 binds molecular oxygen at the 
4α position of the isoalloxazine ring resulting in a 4α-hydroperoxyflavin adenine 
dinucleotide (FAD-OOH) formation (3); when a suitable substrate, such as S in 
methylthioalkyl, binds to the protein/FAD-OOH complex it is oxygenated to SO through 
the OOH moiety (4); the oxygen atom reacts to form water, NADP is released and binding 
of another NADPH starts a new cycle (5) [11,18,19]. 
 
In this reaction, MTHFR transfers a hydride ion from the nicotinamide C4 to 
methylenetetrahydrofolate using a flavin adenine dinucleotide N5 atom as an intermediate hydride 
acceptor and donor [26]. MTHFR is the only enzyme known to catalyze the direct exchange of hydride 
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between folate and FAD [22,25,26,29]. It was shown that the bacterial enzyme-bound flavin was 
reduced by NADH, and much more slowly by NADPH while the mammalian enzymes use  
NADPH [24,26,28]. Reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate creates 
tetrahydrofolate-bound one-carbon units used in the methylation of homocysteine to form methionine, 
the terminal step in methionine biosynthesis [21–26,28–30].  
5,10-Methylenetetrahydrofolate reductase is a multicomponent enzyme consisting of 2–4 subunits, each 
of them containing a molecule of non-covalently bound flavin adenine dinucleotide [21,24,26,28,29,31]. 
Human MTHFR gene has been localized at the end of the short arm of chromosome 1 (1p36.3). It 
encodes a polypeptide of 77 kD which forms homodimers of about 150 kDa [22,29,32]. Each subunit 
of MTHFR comprises a catalytic and a regulatory domain. The 40 kDa catalytic region of the human 
MTHFR is located within the N-terminal domain. It contains determinants for the binding of FAD, 
NAD(P)H and methylenetetrahydrofolate [28,32]. The regulatory region (37 kDa) of MTHFR, which 
is responsible for binding of adenosylmethionine/adenosylhomocysteine (AdoMet/AdoHcy) is located 
at the C-terminal fragment of the molecule. It was shown that MTHFR activity is allosterically 
regulated by the AdoMet/AdoHcy ratio, with AdoMet as an inhibitor and AdoHcy competing with 
AdoMet for binding to the enzyme but not acting as an inhibitor [28,32]. If the cell is repleted with 
AdoMet and the ratio of AdoMet/AdoHcy is high, then the MTHFR is inhibited [29,33]. Both catalytic 
and regulatory domains of human MTHFR are connected by an extremely hydrophilic region  
(Lys-Arg-Arg-Glu-Glu-Asp) [28,32].  
There are two well-described, frequently occurring polymorphisms in the MTHFR gene: c.677C > T 
and c.1298A > C (GenBank accession number U09806). The c.677C > T polymorphism lies at the base 
of the binding site for the FAD. It causes an alanine-to-valine substitution, producing a thermolabile 
form of the enzyme, and has been associated with reduced enzyme activity [29,34,35]. The 
thermolabile form of the MTHFR enzyme has been shown to dissociate with the FAD cofactor more 
readily (approximately 10 times) than wild-type enzyme [3,29,31,36,37]. c.1298A > C polymorphism 
is located in exon 7 coding the S-adenosylmethionine-regulatory domain of the enzyme. It results in a 
glutamate-to-alanine substitution at codon 429 (E429A).  
MTHFR is one of the key enzymes in one-carbon metabolism in which homocysteine, a nonprotein 
forming, sulfur-containing amino acid plays a crucial role (Figure 2). MTHFR regulates the flow of 
folates between the production of nucleotides and the supply of methyl groups for methionine 
synthesis [38,39]. As it was previously mentioned, riboflavin is the precursor of FAD which serves as 
the cofactor for MTHFR and, therefore, riboflavin deficiency may reduce the enzyme activity. 
Reduced ability of the enzyme to catalyze the conversion of 5,10-methylenetetrahydrofolate to  
5-methyltetrahydrofolate leads to hyperhomocysteinemia [27,29]. Elevated plasma homocysteine 
concentrations are associated with several metabolic disorders, including high body mass index, high 
plasma triglyceride levels, hypertension, and abnormal oxidation of low density lipoprotein, which 
may lead to the development of a wide variety of cancers, such as breast, ovarian, and pancreatic 
cancers [40,41]. Additionally, the activity of MTHFR is also a determinant of the availability of folate 
for DNA methylation.  
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Figure 2. Schematic illustration of the one-carbon metabolism/pathways noting  
the cross-talk between DNA synthesis and methylation processes. MTHFR  
(5,10-methylenetetrahydrofolate reductase) transfers a hydride ion from the nicotinamide 
to methylenetetrahydrofolate using flavin adenine dinucleotide as an intermediate  
hydride acceptor and donor (1, 2); reduction of 5,10-methylenetetrahydrofolate to  
5-methyltetrahydrofolate commits tetrahydrofolate-bound one-carbon units to use in the 
methylation of homocysteine to form methionine (3); methionine is converted to 
adenosylmethionine (AdoMet), which serves as a methyl donor for biosynthetic  
reaction (4, 5); adenosylhomocysteine (AdoHcy) is hydrolyzed to adenosine and  
homocysteine (6) [26,27,40], modified. 
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Any disturbance in homocysteine metabolism disturbs cellular methylation processes and DNA 
hypomethylation is a feature of early tumorgenesis and is associated with cancer development. Plasma 
total homocysteine (tHcy) concentration is a responsive indicator of B2, B6, B12 and MTHFR  
status [38]. In patients with hyperhomocysteinemia, increased concentration of homocysteine 
thiolactone, which can react with lysine residues and free amine groups on numerous cellular proteins,  
was observed [40,42]. 
Numerous studies have shown that polymorphisms in the gene-encoding methylenetetrahydrofolate 
reductase may impede homocysteine remethylation [34,39]. A common mutation (c.677C > T) 
described earlier, has been identified with a frequency of 0.32 in the Caucasian population. Individuals 
homozygous for this mutation (TT) have about 30%–35% of the normal MTHFR activity.  
The homocysteine remethylation catalyzed by methionine synthase involves its conversion to 
methionine by the transfer of a methyl group from 5-methyltetrahydrofolate, the major circulatory 
form of folate, and is thought to be the most important reaction affecting plasma tHcy [39–41,43]. The 
relationship between riboflavin status and tHcy concentration is confined mainly to subjects with  
the T allele but not in subjects with the CC genotype. It has been shown by various  
authors [3,29,31,36,37] that the thermolabile form of the MTHFR enzyme dissociates with FAD 
cofactor more readily than wild-type enzyme. Therefore, subjects with T allele may require higher 
concentration of FAD for maximal catalytic activity. This may explain an increased level of tHcy at 
low levels of riboflavin. It was suggested that riboflavin deficiency causes an increased oxidation state 
of the folate pool and a reduction in the relative amounts of 5-methyltetrahydrofolate [44]. Both 
riboflavin and folate can protect against loss of function of MTHFR and, in consequence, can reduce 
the risk of cancer (Figure 3) [45].  
Figure 3. The interrelationship between methylenetetrahydrofolate reductase (MTHFR) 
genotype, riboflavin and folic acid with respect to (a) cytosine-phosphate-guanosine 
dinucleotide (CpG) methylation and uracil in DNA; (b) initiation of cancer caused by  
CpG hypomethylation. The level of riboflavin and folic acid depends on  
supplementation [3], modified. 
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Riboflavin intake was a determinant of total homocysteine in men and women in the Framingham 
Offspring Cohort. In individuals with the TT genotype and a low folate status from the same 
population, total homocysteine was inversely proportional to plasma riboflavin concentration [31,45]. 
On the base of these results it has been postulated that riboflavin status may influence on the 
metabolism of reduced folates, particulary in individuals with the MTHFR T variant. Individuals with 
TT and, possibly, CT genotypes may require a higher level in cytoplasm both folate and riboflavin to 
overcome the partial metabolic block and retain low total homocysteine concentrations [3,44,45]. 
Studies on riboflavin-deficient populations are needed to evaluate the utility of riboflavin 
supplementation in hyperhomocysteinemia [46]. 
4. FAD as an Important Cofactor for the Demethylation of Histones 
Histones pack the eukaryotic DNA into the nucleosome, basic structural unit of chromatin. These 
alkaline proteins, and, in particular, their N-terminal tails, are substrates for a number of covalent  
post-translational modifications which are involved in chromatin remodeling and closely linked to 
transcriptional regulation, DNA replication, and DNA repair [47–50]. Histone acetylation and 
methylation of the lysine and arginine residues represent the most common modifications [48,51]. The 
methylation of lysine is one of the most extensively characterized epigenetic marks involved in the 
regulation of fundamental processes, such as heterochromatin formation, X-chromosome inactivation, 
and DNA repair [50,52]. Each of the methylated lysine residues can be un-, mono-, di-, or 
trimethylated, and the extent of methylation at a specific residue is important for the recognition of 
effector proteins and thus has impact on chromatin and the transcriptional outcome [48,51]. 
Histone lysine modification is a dynamic process established by specific lysine methyltransferases 
and demethylases interactions. Until now, two families of enzymes involved in demethylation of 
methylated lysine residues have been described in humans. The first class comprises jumonji  
domain-containing (JmjC) demethylases, while the second is represented by the amine oxidase 
domain-containing enzymes LSD1 and LSD2, also known as KDM1A and KDM2B. LSD1/2 catalyse 
demetylathion of mono- and dimethylated lysine 4 of histone H3 (H3K4) [49,53–56] but not 
trimethyllysine residues, as the quaternary ammonium group cannot form the requisite imine 
intermediate [57]. Despite the fact the same H3-Lys4 demethylase activity, LSD2 functions in distinct 
transcriptional compexes with specific biological functions [58].  
LSD1 and LSD2 are flavin-dependent amine oxidases closely related to the polyamine oxidase 
superfamily [52,53,56]. LSD1 is an asymmetric molecule consisting of an N-terminal SWIRM domain 
(named for its presence in the proteins Swi3, Rsc8, and Moira) and C-terminal an AOL (amine 
oxidase-like) domain containing sites to bind the methylated substrate and FAD cofactor [47,50,52,53,59]. 
N- and C-terminal domains of LSD1 form a globular core structure from which the third domain, 
named Tower domain, protrudes as an elongated helix-turn-helix motif [59]. This domain is important 
for the histone demethylase activity of LSD1 and may also act as an adaptor to recruit other  
proteins [60]. According to Chen et al. [60] SWIRM domain of LSD1 is composed of five α-helices 
surrounding a central long helix, SWα4, and additional two-stranded β-sheet formed between the 
SWα4- SWα5 loop and the C terminus of the SWIRM domain [60]. This N-terminal motif important 
for protein stability, is thought to be responsible for the association of the enzyme with a variety of 
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transcriptional protein complexes, protein–protein and DNA–protein interactions [49].  
C-terminal amine oxidase-like domain of this protein folds into FAD-binding subdomain and a 
substrate-binding subdomain, thereby creating a big cavity which defines the enzyme activity center at 
their interface. The FAD-binding subdomain shows a mixed α-β structure while the substrate-binding 
subdomain is characterized by a six-stranded mixed β-sheet flanked by six α-helices [49,60]. The large 
cavity of the catalytic center of LSD1 is framed by many structural elements which surround the 
catalytic center. A six-stranded β-sheet and a long helix form its left side and the bottom surfaces, 
respectively, while a short one-turn helix together with a two-stranded β-sheet, and several loops cover 
the rest of the cavity. The left side of the catalytic cavity is flat and composed mainly of hydrophobic 
residues. Its right side presents mainly the acidic side chains and the backbone carbonyl oxygen atoms 
on the concave-shaped surface [60]. The crystal structure of LSD1 revealed a series of hydrogen bond 
and van der Waals interactions between the side chains of H3 residues and those of the LSD1  
active site [52,58].  
Although LSD1 and LSD2 share a similar catalytic domain, they differ in the domains which are 
involved in protein–protein interactions [50,55]. In contrast to LSD1, LSD2 lacks the Tower domain 
which is instrumental to the formation of the complex of LSD1 with its corepressor protein, CoREST. 
Moreover, it contains a CW-type zinc finger motif with potential zinc-binding sites in its N-terminal 
region, which is not present in LSD1. It is suggested that this unique structure of LSD2 may confer its 
biochemical and biological properties as distinct from those of LSD1 [50,61].  
The catalytic turnover of the lysine-specific histone demethylases (LSD1/2) proceeds as expected 
for FAD-dependent amine oxidases. Simultaneous amine oxidation and flavin reduction are followed 
by the re-oxidation of flavin by one equivalent of molecular oxygen, producing stoichiometric 
hydrogen peroxide along with formaldehyde as the demethylation by-product [48,52]. The first step in 
the reaction catalyzed by these enzymes is the flavin-mediated two-electron oxidation of the 
methylated lysine. It leads to the formation of the corresponding imine molecule with the concomitant 
reduction of the flavin cofactor [47]. Following the imine formation, hydration to the N,O-hemiacetal 
and subsequent collapse to formaldehyde and amine takes place [52]. Reduced FAD can be re-oxidized 
by molecular oxygen with formation and release of hydrogen peroxide which makes the enzyme 
available for a new catalytic cycle (Figure 4) [49]. On the basis of changes in the flavin optical 
spectrum it was shown that flavin oxidation is rapid [52]. Baron et al. [58] highlighted the role of 
Lys661 as the “entry residue” which channel the oxygen into the active center of LSD1 and suggested 
its catalytic function in oxygen activation through the electrostatic stabilization of the  
superoxide-flavin semiquinone pair, which is thought to transiently form during the electron-transfer 
process underlying flavin re-oxidation [58]. 
The major unraveled portion of the oxidative conversion of the amine to the imine is the reductive 
half-reaction, which involves the irreversible CH bond cleavage. To date, three major mechanisms for 
this reaction have been discussed: hydride transfer mechanism, polarnucleophilic mechanism, and 
single electron mechanism [52,62]. Hydride transfer mechanism involves a direct transfer of a hydride 
from the substrate α-carbon to flavin without the intermediacy of carbanion (Figure 4). In contrast, the 
polar nucleophilic mechanism and a radical mechanism require additional intermediates, an adduct 
intermediate and radical intermediate, preceding the CH cleavage [62,63]. The absence of detectable 
intermediates between oxidized and reduced FAD, as well as the unfavorable energetic for the polar 
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nucleophilic mechanism and radical mechanism, suggests that the rate-limiting reductive half-reaction 
of LSD1 employed the direct hydride transfer mechanism [62]. 
Figure 4. Mechanism of lysine demethylation by LSD1. Simultaneous amine oxidation 
and flavin reduction are followed by the re-oxidation of flavin by one equivalent of 
molecular oxygen, producing stoichiometric hydrogen peroxide along with the 
formaldehyde as the demethylation by-product [48,52]. Flavin dependent amine oxidase 
(LSD1) catalyzes the flavin-mediated two-electron oxidation of the methylated lysine; it 
leads to the formation of the corresponding imine molecule with the concomitant reduction 
of the flavin cofactor (1, 2); following the imine formation, hydration to the N,O-hemiacetal 
and subsequent collapse to formaldehyde and amine takes place (3, 4); reduced FAD can 
be re-oxidized by molecular oxygen to hydrogen peroxide (5) [47,48,56,62,64], modified. 
 
A significant number of lysine and arginine residues on the histone tails and various methylation 
levels which can be generated at each of these sites, provide tremendous regulatory potentials for 
chromatin modifications [52,55,65,66]. Although LSD1 alone is capable of demethylating H3K4 in 
peptides, demethylation of H3-K4 in nucleosomes by LSD1 requires corepressor CoREST. CoREST 
and LSD1 form very tight and stabilizing complex which does not dissociate even at very high ionic 
strength [50,58]. This complex is an exceptionally relevant target for epigenetic drugs because LSD1 is 
overexpressed in many solid tumors such as breast, colon, neuroblastoma, bladder, small cell lung, 
blood, and prostate cancers [67]. Moreover, LSD1 may play an important role in facilitating androgen 
receptor-mediated transcriptional regulation [48,49,65]. Recent reports suggest that increased LSD1 
expression in prostate tumors correlates significantly with relapse during therapy [57,65]. 
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LSD1 might also act on a non-histone substrate such as p53 which activates the expression of genes 
involved in either cell cycle arrest or apoptosis in response to DNA damage. Demethylation of 
methylated p53 prevents it from binding DNA and leads to inactivation of p53 target genes [51,57,68]. 
It has been shown that LSD1 also participates in the repression of E-cadherin, a molecule mediating 
cell–cell interaction and migration. Downregulation of this factor generally correlates with poor 
prognosis of tumor and metastasis. Although LSD1 could have an oncogenic effect, it could behave as 
a tumor suppressor [69]. Studies of Wang et al. [54] indicated a role for LSD1 in suppressing breast 
cancer metastasis by repressing TGFβ1 expression. LSD1 expression was significantly lower in tumor 
samples compared to adjacent normal tissue and the level of LSD1 expression was negatively 
correlated with the level of TGFβ1 expression.  
Flavin-dependent histone demethylases represent potential targets for chemotherapy [52,55,66,69]. 
Such inhibitors as tranylcypromine ((±)-trans-2-phenylcyclopropyl-1-amine HCl) are of potential 
relevance for the treatment of promyelocytic leukemia and may be used to block tumor  
progression [53,55,69]. It was shown that this nonselective MAO inhibitor can be covalently attached 
to FAD N(5) and can act as a sort of plug which fills the substrate-binding cleft of LSD1. Moreover, 
Yang et al. [66] reveled that phenyl group of the FAD-tranylcypromine adduct in LSD1 is located in a 
large hydrophobic pocket and does not form extensive contacts with the surrounding residues. It 
suggests that tranylcypromine analogs with hydrophobic substitutions on the phenyl ring might be 
more potent inhibitors of LSD1 [70]. Culhane et al. [70,71] showed inhibition of LSD1 by  
propagyl-Lys-derivatived peptide and phenelzine. Schulte et al. [72] observed that treatment of 
neuroblastoma cell lines with the pargyline, clorgyline, or tranylcypromine impaired growth of 
neuroblastoma cells. Reduced viability of these cells was correlated with increased global 
dimethylation of lysine 4 in histone 3 [72]. Karytinos et al. [50] revealed that tranylcypromine is also 
an LSD2 inhibitor, while other monoamine oxidase covalent inhibitors such as pargyline, deprenyl, 
and rasagiline, did not exert any inhibitory effect on LSD2. 
5. The Role of Riboflavin Supplements in the Prevention of Cancer  
Dietary intake of riboflavins could play an important role in the development and progression of 
cancer. Riboflavin deficiency interferes with the metabolism of other B vitamins, through flavin 
coenzyme activity. As was already mentioned, riboflavin is the precursor of FAD, the cofactor for 
methylenetetrahydrofolate reductase, and, by that means, its status influences the metabolism of folates 
and, consequently, the risk of cancer [2]. 
Free riboflavin is present in food in small amounts, while most of it occurs as one of its coenzyme 
derivatives: FAD and FMN. However, flavins which are covalently bound to the enzymes do not 
appear to be available for absorption, which occurs through carrier-mediated transport process 
predominantly in the proximal small intestine but also in the colon [1].  
The recommended dietary allowance for riboflavin is 1.1 and 1.3 mg/d for women and men, 
respectively [73]. As cereals, milk, dairy products, meat, and fatty fish, as well as fruits and dark-green 
leafy vegetables are good sources of riboflavin intake [2,73], in Western countries, riboflavin deficiency 
is uncommon. However, deficiency is possible for children, adults who avoid drinking milk, and 
athletes with concerns about body weight [73,74]. Riboflavin deficiency is endemic in many developing 
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countries in populations which exist on diets lacking dairy products and meat. However, riboflavin 
synthesized by bacterial metabolism in the colon might be an important source of this vitamin [1]. 
He et al. [75] investigated the influence of riboflavin-fortified salt nutrition on the risk of 
esophageal cancer—the sixth most common cancer on the globe—which causes the highest mortality 
among the Chinese, whose diet is poor in riboflavin. It has been shown that riboflavin was a protective 
factor for this type of cancer incidence [75]. Association between dietary intakes of riboflavin and 
colorectal, cervical, breast, and prostate cancer incidence and mortality was also found [2,4–6,76]. 
Riboflavin captures reactive metabolites like tamoxifen and carcinogens to form a complex, thereby 
preventing formations of DNA adduct, preventing DNA methylation, and maintaining genomic 
stability. It is speculated that it protects against DNA damage by increasing the levels of poly(ADP-ribose) 
polymerase [6]. Premkumar et al. [6] determined the influence of riboflavin supplementation  
(10 mg one dose per day) on the breast cancer patients undergoing tamoxifen therapy. It is especially 
important because cancer patients are exposed to high levels of DNA-damaging agents and they may 
also reveal cancer cachexia connected with chemotherapy. Additionally, cancer cells with inhibited 
repair-associated enzymes cannot be efficiently repaired, which leads to the cell death [6]. It was shown 
that riboflavin binds chemioterapheutics and carcinogens to form a complex, and, in this way, prevent 
formation of DNA adducts and DNA methylation, while maintaining genomic stability. Moreover, 
riboflavin supplementation influences induction of repair enzymes such as poly(ADP-ribose) 
polymerase, DNA polymerase beta and DNA ligase [6].  
Riboflavin is a cofactor for 5,10-methylenetetrahydrofolate reductase. Low intake of this vitamin 
reduces the metabolic activity of MTHFR and thus contributes to colorectal carcinogenesis. MTHFR 
c.677C > T polymorphism also affects enzyme activity and therefore can be associated with reduced 
colorectal cancer risk with adequate riboflavin and folate status [4,5,77]. Such association was 
observed by Powers [4]. In this study, subjects were divided into three groups: placebo group,  
low-dose folate group (400 μg folic acid and 5 mg riboflavin), and high-dose folate group (1.2 mg folic 
acid). The riboflavin supplementation enhanced the systemic response to low-dose folic acid in the 
patients with at least one T allele [4]. Powers et al. [5] suggested that riboflavin can partially 
compensate for the reduction in 5,10-methylenetetrahydrofolate reductase activity in heterozygotes and 
homozygotes for the c.677C > T mutation, through its cofactor role for this enzyme. McNulty et al. [37] 
confirmed in their study that persons carrying the TT genotype for MTHFR are particularly sensitive to 
riboflavin status to maintain adequate folate status and to prevent the accumulation of homocysteine.  
De Vogel et al. [77] studied the relationship between riboflavin intake and colorectal cancer risk. They 
showed that riboflavin level was associated with decreased proximal colon cancer risk among women. 
Gender-specific cancer risk can most likely be connected with higher sensitivity of proximal colon 
cells in women on riboflavin level, which indirectly leads to differences in DNA hypomethylation 
between men and women [77]. 
No association between dietary intake of riboflavin and prostate cancer was detected by  
Basset et al. [2]. There was a suggestive evidence of an inverse U-shaped relationship between 
incidence and both riboflavin and folate intake and between mortality and riboflavin intake. 
Additionally, significant interaction between alcohol and riboflavin was observed [2].  
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6. Conclusions  
The effect of dietary deficiency of riboflavin on the tumor growth was first noted in 1943. Since 
then, our knowledge about complex interactions between riboflavins and various enzyme functions, as 
well as regulation of metabolism, has increased significantly. Now, it is known that the distribution of 
riboflavin, FMN, and FAD in tissues is under strict metabolic control and the flavin-dependent 
enzymes play an important role, e.g. in demethylation of histons and stabilization of homocysteine 
level in one-carbon metabolism. These enzymes are also engaged in biosynthesis of plant secondary 
metabolites such as glucosinolates involved in detoxification of carcinogenic and/or mutagenic 
compounds. Therefore from a public health perspective, it is important to identify factors which may 
be an effective strategy for the prevention of cancer, including riboflavin supplementation.  
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